24829-91-2

Upstream product

• 765-87-7 cyclohexane-1,2-dione 

Downstream Products

• 1235494-96-8 2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-6,7-dihydrobenzo[d]thiazol-4(5H)-one 
• 36234-66-9 2-amino-6,7-dihydrobenzo[d]thiazol-4(5H)-one 
• 1314243-55-4 C₁₄H₁₃NO₂S 
• 1314243-69-0 C₁₃H₁₂N₂O₂ 
• 1314243-54-3 C₁₆H₁₇NOS 
• 1314243-68-9 C₁₄H₁₄N₂O₂ 
• 1314243-53-2 C₁₃H₉Cl₂NOS 
• 1314243-65-6 C₁₄H₁₂ClNO₃S₂ 
• 1314243-56-5 C₁₅H₁₃NO₃S 
• 1314243-52-1 C₁₃H₁₁NOS 
• 1314243-63-4 C₁₄H₁₄N₂O₂S 
• 1314243-60-1 C₁₄H₁₃NOS 
• 1088713-97-6 ethyl 2-(2-fluoro-4-iodophenylamino)-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 
• 1088714-05-9 ethyl 2-(4-bromo-2-fluorophenylamino)-7-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylate 

Relevant academic research and scientific papers

3-Bromocyclohexane-1,2-dione as a useful reagent for Hantzsch synthesis of thiazoles and the synthesis of related heterocycles

We describe the use of 3-bromocyclohexane-1,2-dione, an air stable, versatile reagent for the Hantzsch thiazole synthesis and the synthesis of other closely related heterocycles.

ARYLAMIDES AND METHODS OF USE THEREOF

The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

CXCR2 ANTAGONIST

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted hydrazone compounds, methods of making such compounds and metal complexes thereof, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds and metal complexes to treat, prevent or ameliorate cancer are provided.

TDO2 INHIBITORS

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

Discovery of imidazo[2,1- b ]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents

The design, synthesis, and SAR studies of novel inhibitors of HCV NS4B based on the imidazo[2,1-b]thiazole scaffold were described. Optimization of potency with respect to genotype 1b resulted in the discovery of two potent leads 26f (EC50 = 16

HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to compounds of formula (1) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

The present disclosure provides a series of compounds of the formula (I) which reduce β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production, wherein